- Home
- WLYB vs TARS Comparison
WLYB vs TARS Comparison
Compare WLYB & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLYB
- TARS
- Stock Information
- Founded
- WLYB 1807
- TARS 2016
- Country
- WLYB United States
- TARS United States
- Employees
- WLYB N/A
- TARS N/A
- Industry
- WLYB Books
- TARS Medicinal Chemicals and Botanical Products
- Sector
- WLYB Consumer Discretionary
- TARS Health Care
- Exchange
- WLYB Nasdaq
- TARS Nasdaq
- Market Cap
- WLYB 2.1B
- TARS 1.7B
- IPO Year
- WLYB N/A
- TARS 2020
- Fundamental
- Price
- WLYB $42.11
- TARS $51.69
- Analyst Decision
- WLYB
- TARS Strong Buy
- Analyst Count
- WLYB 0
- TARS 7
- Target Price
- WLYB N/A
- TARS $67.14
- AVG Volume (30 Days)
- WLYB 238.0
- TARS 679.4K
- Earning Date
- WLYB 09-04-2025
- TARS 11-12-2025
- Dividend Yield
- WLYB 3.34%
- TARS N/A
- EPS Growth
- WLYB N/A
- TARS N/A
- EPS
- WLYB 1.78
- TARS N/A
- Revenue
- WLYB $1,670,600,000.00
- TARS $295,521,000.00
- Revenue This Year
- WLYB $1.45
- TARS $33,170.29
- Revenue Next Year
- WLYB $2.70
- TARS N/A
- P/E Ratio
- WLYB $23.00
- TARS N/A
- Revenue Growth
- WLYB N/A
- TARS 254.45
- 52 Week Low
- WLYB $37.27
- TARS $30.23
- 52 Week High
- WLYB $52.90
- TARS $59.76
- Technical
- Relative Strength Index (RSI)
- WLYB 67.63
- TARS 46.25
- Support Level
- WLYB $39.63
- TARS $48.20
- Resistance Level
- WLYB $42.54
- TARS $59.76
- Average True Range (ATR)
- WLYB 0.01
- TARS 2.04
- MACD
- WLYB 0.22
- TARS -1.29
- Stochastic Oscillator
- WLYB 84.01
- TARS 30.19
About WLYB John Wiley & Sons Inc.
John Wiley & Sons Inc is one of the world's greatest publishers and a trusted leader in research and learning. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.